# The Emerging Role of miRNAs and Their Clinical Implication in Biliary Tract Cancer

Authors: Nina Nayara Ferreira Martins; Kelly Cristina da Silva Oliveira; Amanda Braga Bona; Marília de Arruda Cardoso Smith; Geraldo Ishak; Paulo Pimentel Assumpção; Rommel Rodríguez Burbano; Danielle Queiroz Calcagno
Journal: Gastroenterology Research and Practice
 (2016)

---

## Abstract

Biliary tract cancers are aggressive malignancies that include gallbladder cancer and tumors of intra- and extrahepatic ducts and have a poor prognosis. Surgical resection remains the main curative therapy. Nevertheless, numerous patients experience recurrence even after radical surgery. This scenario drives the research to identify biliary tract cancer biomarkers despite the limited progress that has been made. Recently, a large number of studies have demonstrated that deregulated expression of microRNAs is closely associated with cancer development and progression. In this review, we highlight the role and importance of microRNAs in biliary tract cancers with an emphasis on utilizing circulating microRNAs as potential biomarkers. Additionally, we report several single-nucleotide polymorphisms inmicroRNA genes that are associated with the susceptibility of biliary tract tumors.


---

## Body

## 1. Background

Despite their relatively rare incidence, biliary tract cancers (BTCs) are an aggressive tumor group with poor prognosis and are characterized by early lymph node and systemic metastases [1]. These tumors include gallbladder cancer (GBC) and cholangiocarcinoma (CCA), which is divided into intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA). Currently, surgical resection remains the only curative treatment for BTCs, and neoadjuvant chemoradiotherapy is not a standard option for patients with these malignancies. Moreover, many cases present with recurrence even after radical surgery, and patients with recurrent or metastatic BTCs usually have a poor outcome [2]. Therefore, there is a need for additional investigations to determine potential biomarkers of BTCs for early diagnosis, determining patient prognosis and the development of targeted therapy.Recent studies have described microRNAs (miRNAs) as potential biomarkers in different cancer types [3–6]. However, miRNA expression and their implications in the diagnosis of, prognosis of, and therapeutic applications towards BTCs remain elusive.miRNAs are small noncoding RNAs (18–25 nucleotides) that play important roles in the regulation of a large number of essential biological functions that are critical to the development of different cancer types, including cell proliferation, differentiation, apoptosis, migration, and invasion [7].miRNA biogenesis initiates in the nucleus, where miRNA genes are usually transcribed by RNA polymerase II, resulting in a primary transcript of miRNA (pri-miRNAs) [8]. During the initial processing of pri-miRNAs, the Drosha-DGCR8 complex cleaves the pri-miRNA, releasing a hairpin structure named pre-miRNA (~70 nucleotides). Pre-miRNAs are transferred to the cytoplasm and converted into an miRNA duplex by Exportin-5 and the Dicer-TRBP complex, respectively. Then, a helicase separates the double-stranded miRNA to produce one stable single-stranded miRNA, while the other strand is processed for autolytic degradation. The stable mature miRNA strand is loaded into the RNA-induced silencing complex (RISC) to mechanistically target the 3′ untranslated regions (3′UTRs) of protein coding mRNAs, thereby acting as posttranscriptional regulators by two mechanisms: mRNA degradation (when the sequences are perfect complements) and inhibition of translational initiation (when there is partial complementarily) [9]. Thus, miRNAs act as negative regulators of posttranscriptional gene expression of target mRNAs.It has been well established that miRNAs could regulate approximately 60% of human genes, including many oncogenes and tumor suppressor genes; this phenomenon strengthens the importance of these noncoding RNAs as relevant regulators in cancer [10].In this review, we focus on the roles and importance of miRNAs in BTCs and highlight the potential of circulating miRNAs as diagnostic and prognostic biomarkers. Therefore, we reported several single-nucleotide polymorphisms (SNPs) inmiRNA genes associated with BTC susceptibility.


## 2. Roles and Clinical Significance of miRNAs in BTCs

A large number of deregulated miRNAs have been categorized as oncomiRs (oncogene miRNAs) and/or tsmiRs (tumor suppressor miRNAs) in cancer depending on the effect of the target mRNA.In BTCs, several studies on miRNA expression have identified many upregulated oncomiRs and downregulated tsmiRs as well as their potential targets (Table1).Table 1
Deregulated miRNAs in BTCs.
miRNA Tumor Expression Target Roles in BTCs Reference hsa-miR-21 CCA ↑ PTEN InvasionMigration Chemoresistance [11–14] ↓ TPM1 DNA methylation Histone deacetylation [15] ↓ 15-PGDH Inflammation [16] HPGD ↑ PDCD4 Lymph node metastasisMigration [17–20] ↑ RECK MigrationMetastasis [21, 22] ↑ TIMP3 Apoptosis [18] ↑ — pTNMPrognosis [23]  hsa-miR-20a GBC ↑ SMAD7 InvasionMetastasisMigration Prognosis [24]  hsa-miR-34a CCA ↓ C-MYC Progression [25] GBC ↓ PNUTS ProliferationPrognosis [26]  hsa-miR-335 GBC ↓ BMI1 InvasionLymph node metastasispTNMPrognosis [27, 28]  hsa-miR-148a CCA ↓ DNMT1 Prognosis [29]  hsa-miR-31 CCA ↑ RASA1 ApoptosisProliferation [30]  hsa-miR-200b/c CCA ↓ SUZ12 ChemoresistanceInvasionMigration [28]  hsa-miR-210 CCA ↑ MNT Progression [25]  Let-7a CCA ↓ RAS Progression [21]  hsa-miR-370 CCA ↓ MAP3K8 InflammationpTNM [31]  hsa-miR-29b CCA ↓ C-MYC Apoptosis [32]  hsa-miR-101 CCA ↓ VEGF Angiogenesis [33] COX-2  hsa-miR-200b/c CCA ↓ ROCK2 Migration [28]  hsa-miR-138 CCA ↓ RHOC Migration [34]  hsa-miR-376c CCA ↓ GRB2 Migration [35]  hsa-miR-124 CCA ↓ SMYD3 Migration [36]  hsa-miR-204 CCA ↓ SLUG Migration [37]  hsa-miR-214 CCA ↓ TWIST Migration [38]  hsa-miR-200c CCA ↓ NCAM1 Migration [39]  hsa-miR-200b CCA ↑ PTPN12 Chemoresistance [14]  hsa-miR-29b CCA ↓ PIK3R1 Chemoresistance [40] MMP2 hsa-miR-205 CCA ↓ — Chemoresistance hsa-miR-221 CCA ↓ PIK3R1 Chemoresistance  hsa-miR-182 GBC ↑ CADM1 InvasionMigrationMetastasis [27]  hsa-miR-155 GBC ↑ SMAD7 InvasionLymph node metastasis ProliferationPrognosis [41]  hsa-miR-130a GBC ↓ HOTAIR InvasionProliferation [42]  hsa-miR-26a GBC ↓ HMGA2 pTNMProliferation [43]  hsa-miR-135a-5p GBC ↓ VLDLR pTNMProliferation [44]  hsa-miR-218-5p GBC ↓ BMI1 InvasionMigration Proliferation [45]  hsa-miR-146-5p GBC ↓ EGFR ApoptosispTNMProliferation [46]  hsa-miR-1 GBC ↓ VEGF-A ApoptosisProliferation [47] AXL hsa-miR-145 GBC AXL hsa-miR-143 GBC ↓ AXL Lymph node metastasispTNM stage hsa-miR-122hsa-miR-187 GBC ↑One of the best-described miRNAs in BTCs is hsa-miR-21, which is usually identified as an oncomiR since its overexpression has been associated with invasion and metastasis [11–19, 21–25, 27, 30, 41, 47–50]. Liu et al. [13] observed that overexpression of hsa-miR-21 significantly promotes cell migration, invasion, and xenograft growth after transfection of hsa-miR-21 into CCA cell lines (QBC939 and RBE). Moreover, these authors showed decreased E-cadherin expression and increased N-cadherin and vimentin expression after hsa-miR-21 overexpression. Thus, hsa-miR-21 could induce the epithelial-mesenchymal transition (EMT) in CCA. In this process, epithelial cells lose their cell polarity and cell adhesion—probably due to the decrease of E-cadherin expression—which allows cells to migrate and invade surrounding tissues; this the loss of E-cadherin expression plays a key role in tumor invasion and metastasis.Similarly, aberrant expression of miRNAs also induces EMT and enhances the metastatic potential of GBC cells [24, 51]. Bao et al. [51] reported that hsa-miR-101 overexpression inhibits the proliferation, migration, and invasion of GBC cells, induces the increased expression of E-cadherin and β-catenin, and causes decreased expression of vimentin. Furthermore, these authors observed that hsa-miR-101 downregulation was correlated with tumor size, invasion, lymph node metastasis, TNM stage, and poor survival in GBC patients. These results indicate that hsa-miR-101 plays a tsmiR role and attenuates EMT and metastasis in GBC.Accumulating evidence has indicated that hsa-miR-146b-5p presents critical tumor suppressor properties [52, 53]. Its expression was significantly downregulated in GBC tissue compared with adjacent nonneoplastic tissues. In addition, the overexpression of hsa-miR-146b-5p in the SGC-996 GBC cell line inhibited cell growth by enhancing apoptosis and arresting the cells at G1 phase. However, the enforced expression ofEGFR, a cell surface protein that binds to epidermal growth factor (which inducing cell proliferation), reversed the ability of hsa-miR-146b-5p to inhibit proliferation. Moreover, hsa-miR-146b-5p expression levels were significantly correlated with tumor size and cancer progression [46].Recent studies have described hsa-miR-135a-5p as having a tsmiR role [54–56]. In GBC, Zhou et al. [44] found that hsa-miR-135a-5p levels were significantly downregulated in tumors compared to adjacent nontumor gallbladder tissues and were correlated with neoplasms of histological grades III and IV. Additionally, this study identifiedVLDLR as a direct and functional target gene of hsa-miR-135a-5p in GBC tissues. Furthermore, the transfection with a hsa-miR-135a-5p mimetic inhibited the proliferative and colony-forming abilities of GBC cells by arresting the cells in G1/S phase. These data suggest that hsa-miR-135a-5p may inhibit the proliferation of GBC cells.


## 3. Circulating miRNAs as Potential BTCs Biomarkers

Several studies have reported that detectable miRNAs in bodily fluids (e.g., plasma, serum, urine, and saliva) are more stable in comparison with other circulating nucleic acids [57]. Therefore, circulating miRNAs may be noninvasive and specific diagnostic and/or prognostic molecular biomarkers for human diseases, including cancer [4, 7, 58, 59]. In BTCs, many circulating miRNAs seem to be reproducible and reliable potential biomarkers as well as possible therapeutic targets [60]. Table 2 summarizes the circulating miRNAs with potential diagnostic, prognostic, and predictive biomarker applications in BTCs.Table 2
Circulating miRNAs in patients with BTC as potential diagnostic, prognostic, and predictive biomarkers.
miRNA Expression Samples N samples Potential biomarker Method Clinical implication Reference hsa-miR-9 ↑ Bile BTCs (9)HV (9) DiagnosticPrognostic RT-PCR Metastasis [61]  hsa-miR-145 ↑ Bile BTCs (9)HV (9) Diagnostic RT-PCR — [61]  hsa-miR-21 ↑ Plasma BTCs (94)HV (50)BBD (2) Diagnostic qRT-PCR Inflammatory reaction [62] Peripheral blood GBC (40)HV (40) Diagnostic qRT-PCR — [47]  hsa-miR-150 ↑ Plasma iCCA (15) Diagnostic qRT-PCR Tumor progression [63]  hsa-miR-106a ↓ Serum CCA (103) Prognostic qRT-PCR Lymph node metastasis [64] HV (20)  hsa-miR-126 ↑ Serum PSC (40)CCA (31)HV (12) Diagnostic RT-PCR — [65]  hsa-miR-26a ↑ Serum PSC (40)CCA (31)HV (12) Diagnostic RT-PCR — [65]  hsa-miR-30b ↑ Serum PSC (40)CC (31)HV (12) Diagnostic RT-PCR — [65]  hsa- miR-122 ↑ Serum PSC (40)CC (31)HV (12) Diagnostic RT-PCR — [65]  hsa-miR-1281 ↑ Serum PSC (40)CC (31)HV (12) Diagnostic RT-PCR — [65]  hsa-miR -187 ↑ Peripheral blood GBC (40)HV (40) DiagnosticPrognosticPredictive qRT-PCR Lymph node metastasisPoor prognosis [47]  hsa-miR-192 ↑ Peripheral blood GBC (40)HV (40) DiagnosticPrognosticPredictive qRT-PCR Inflammatory reactionImmune reactionLymph node metastasis [47] Serum iCCA (11)HV (09) DiagnosticPrognostic miRNA RT-PCR array Lymph node metastasisPoor prognosis [66]  hsa-miR-194 ↑ Serum CCA (70)HV (70) Diagnostic qRT-PCR Tumor progression [58]  hsa-miR -202 ↑ Peripheral blood GBC (40)HV (40) DiagnosticPrognosticPredictive qRT-PCR Lymph node metastasis [47]  hsa-let- 7a ↓ Peripheral blood GBC (40)HV (40) Diagnostic qRT-PCR — [47]  hsa-miR -143 ↓ Peripheral blood GBC (40)HV (40) DiagnosticPrognosticPredictive qRT-PCR Inflammatory and immune reactionLymph node metastasis [47]  hsa-miR-335 ↓ Peripheral blood GBC (40)HV (40) Diagnostic qRT-PCR — [47]  hsa-miR-1307-3p ↓ Plasma iCCA (13)HV (5) Diagnostic qRT-PCR — [67]  hsa-miR-1275 ↑ Plasma iCCA (13)HV (5) Diagnostic qRT-PCR — [67]  hsa- miR-320b ↑ Plasma iCCA (13)HVs (5) Diagnostic qRT-PCR — [67]  hsa-miR-874 ↑ Plasma iCCA (13)HVs (5) Diagnostic qRT-PCR — [67]  hsa-miR-483-5p ↑ Plasma iCCA (13)HV (5) Diagnostic qRT-PCR — [67] Serum CCA (70)HV (70) Diagnostic qRT-PCR Tumor progression [58]  hsa-miR-885-5p ↑ Plasma iCCA (13)HV (5) Diagnostic qRT-PCR — [67]  hsa-miR-92b-3p ↑ Plasma iCCA (13)HV (5) Diagnostic qRT-PCR — [67]  hsa-miR-505-3p ↑ Plasma iCCA (13)HV (5) Diagnostic qRT-PCR — [67]  hsa-miR-6836-3p ↑ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]  hsa-miR-6075 ↑ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]  hsa- miR-4634 ↑ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]  hsa-miR-4294 ↓ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]  hsa-miR-6880-5p ↓ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]  hsa-miR-6799-5p ↓ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]  hsa-miR-125a-3p, ↓ Serum BTCs (98)HV (150) Diagnostic 3D-Gene Tumor progression [68]  hsa-miR-4530 ↓ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]  hsa-miR-7114-5p ↓ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]  hsa-miR-4476 ↓ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68] BBD: benign biliary disorders; BTCs: biliary tract cancers; CCA: cholangiocarcinoma; iCCA: intrahepatic cholangiocarcinoma; GBC: gallbladder cancer; HV: heath volunteers; PSC: primary sclerosing cholangitis.In CCA patients, Cheng et al. [64] observed different expression levels of circulating hsa-miR-106a not only between CCAs and healthy controls but also among CCAs and benign bile duct diseases (e.g., primary bile duct stone and congenital biliary duct cysts). Furthermore, they identified decreased hsa-miR-106a levels in patients with lymph node metastasis compared with those without metastasis, indicating the possible role of hsa-miR-106a in the occurrence of lymph node metastasis.Interestingly, Voigtländer et al. [65] found a distinct circulating miRNA profile in the bile and serum samples from CCA patients and patients with primary sclerosing cholangitis (PSC), a noncancerous disease. Furthermore, bile samples from patients with concomitant PSC and CCA (PSC/CCA) were also included in this study. Their results showed higher expression levels of hsa-miR-126, hsa-miR-26a, hsa-miR-30b, hsa-miR-122, and hsa-miR-1281 in PSC patients than those in CCA patients. However, bile samples showed hsa-miR-640, hsa-miR-1537, and hsa-miR-3189 downregulation, as well as hsa-miR-412 upregulation in PSC and PSC/CCA patients. These results demonstrated that PSC and CCA patients have distinct miRNA profiles in their bile and serum, which could be used to discriminate these diseases.A small number of studies have described circulating miRNAs in patients with GBC. Kishimoto et al. [62] demonstrated an increase in the hsa-miR-21 expression levels in plasma from GBC patients before curative resection when compared with postsurgical patients and healthy volunteers. These findings suggest that hsa-miR-21 plasma levels were significantly affected by cancer occurrence and might have the potential to be a diagnostic biomarker for GBC patients.Recently, Li and Pu [47] described significantly deregulated miRNAs in the peripheral blood samples of GBC patients compared with healthy volunteers. The expression levels of hsa-miR-187, hsa-miR-192, and hsa-miR-202 were upregulated while hsa-miR-143 was downregulated. These results were associated with lymph node metastasis, inflammation, immune reaction, and poor prognosis and could be translated to clinical practice as biomarkers for the early diagnosis, prognosis, and predictive response in patients with GBC.Although most studies involving circulating miRNAs utilize real-time PCR for detection, Kojima et al. [68] used a highly sensitive microarray denoted as “3D Gene” that was capable of simultaneously analyzing more than 2,500 miRNAs in serum samples from patients with pancreato-biliary cancers. These authors found several significantly dysregulated miRNAs, including 30 upregulated miRNAs and 36 downregulated miRNAs in BTCs. However, none of these miRNAs could be used as single biomarker for this type of cancer. The best results were achieved with a panel of eight miRNAs (hsa-miR-6075, hsa-miR-4294, hsa-miR-6880-5p, hsa-miR-6799-5p, hsa-miR-125a-3p, hsa-miR-4530, hsa-miR-6836-3p, and hsa-miR-4476).


## 4.miRNA Single-Nucleotide Polymorphisms in BTCs

In general, aberrations in miRNA expression result from either epigenetic modifications or genomic changes, which include chromosomal rearrangements, mutations, or SNPs [69].Several SNPs in miRNAs can lead to distinctions in the miRNA expression levels, which can modulate miRNA-target gene expression and, subsequently, affect cancer susceptibility [4, 70]. However, few studies have been performed to identify SNPs in miRNAs in BTCs patients until now.The SNPs hsa-miR-27a rs895819, hsa-miR-570 rs4143815, and hsa-miR-181a rs12537 have been found to play important roles in many cancer types [71–78], and their contribution in BTCs has been explored. Gupta et al. [70] observed that the combination of hsa-miR-27a rs895819, hsa-miR-570 rs4143815, and hsa-miR-181a rs12537 was the best gene-gene interaction model for predicting the susceptibility and treatment response in GBC patients. Moreover, the SNPs hsa-miR-27a rs895819 and hsa-miR-181a rs12537 were associated with treatment toxicity but had no influence on the survival outcomes of GBC patients with locally advanced and/or metastatic tumors.SNPs in pri-miRNAs and pre-miRNAs could also affect miRNA processing, miRNA expression, and cancer susceptibility. Srivastava et al. [79] reported genetic polymorphisms in pre-mir-196a2 rs11614913 (C>T), pre-hsa-mir-196a rs11614913, and pre-hsa-mir-499 rs3746444 (T>C) that were associated with an increased overall risk of developing GBC development. In CCA, Mihalache et al. [80] investigatedthe G/C variant inpre-hsa-miR-146a rs2910164 and found no significant relationship between genetic susceptibility and CCA.Additional studies addressing the identification of miRNA SNPs could be useful to assess the individual susceptibility of BTCs and improve our understanding of their potential contribution to the disease as well as aid in the development of potential clinical applications.


## 5. Conclusion

miRNAs are profoundly involved in tumor onset and progression [81–84]. However, the implications of miRNA for the diagnosis, prognosis, and therapeutic options for patients with BTCs remain unsatisfactory. This review highlighted some miRNAs that are dysregulated in BTCs, their targets, and the possible clinical implications. A better understanding of the therapeutic applications of miRNAs could lead to future clinical trials involving the inhibition of oncomiRs or the promotion of expression of tsmiRs as new approaches against diverse cancer types, including aggressive BTCs.Here, we also reported several circulating miRNAs as possible diagnostic, prognostic, and/or predictive biomarkers in BTCs. Circulating miRNAs could be promising potential biomarkers for cancers because detectable miRNAs in the bodily fluids are stable and can be measured using noninvasive methods [57]. BTCs are usually asymptomatic; therefore, the use of miRNAs as early diagnostic biomarkers could be a useful tool to improve the long-term survival of BTC patients. However, more studies with clinical outcomes are needed to identify which miRNAs could serve as either a potential therapeutic target or diagnostic and prognostic biomarkers of BTCs.Moreover, several SNPs in miRNAs can affect the expression of target genes, leading to a cellular disorder and, consequently, tumorigenesis [4, 70]. However, few studies have been performed to identify SNPs in the miRNAs expressed by BTC patients until now; this review emphasizes the need to expand the knowledge in this field of study.



---

*Source: 9797410-2016-12-27.xml*